NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis $3.70 +0.05 (+1.37%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.62▼$3.7650-Day Range$2.73▼$3.8552-Week Range$1.45▼$4.91Volume462,303 shsAverage Volume512,627 shsMarket Capitalization$261.06 millionP/E RatioN/ADividend YieldN/APrice Target$7.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Codexis alerts: Email Address Codexis MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside98.2% Upside$7.33 Price TargetShort InterestBearish3.13% of Shares Sold ShortDividend StrengthN/ASustainability-3.67Upright™ Environmental ScoreNews Sentiment0.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.63) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.17 out of 5 starsMedical Sector369th out of 936 stocksIndustrial Organic Chemicals Industry11th out of 17 stocks 3.4 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCodexis has only been the subject of 3 research reports in the past 90 days.Read more about Codexis' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.13% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Codexis has recently increased by 5.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCodexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Codexis is -3.67. Previous Next 1.8 News and Social Media Coverage News SentimentCodexis has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Codexis this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Codexis to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Codexis' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to decrease in the coming year, from ($0.63) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Codexis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Codexis Stock (NASDAQ:CDXS)Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More CDXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXS Stock News HeadlinesJuly 18, 2024 | globenewswire.comCodexis to Report Second Quarter 2024 Financial Results on August 8July 1, 2024 | globenewswire.comCodexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy AssetsJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 22, 2024 | globenewswire.comCodexis to Participate in Jefferies Global Healthcare ConferenceMay 20, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Codexis (CDXS)May 20, 2024 | globenewswire.comCodexis to Participate in TD Cowen 2nd Annual Sustainability WeekMay 14, 2024 | globenewswire.comCodexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual MeetingMay 4, 2024 | finance.yahoo.comCodexis First Quarter 2024 Earnings: Beats ExpectationsJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 3, 2024 | finance.yahoo.comCodexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 3, 2024 | finance.yahoo.comCodexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comCodexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic AdvancesMay 1, 2024 | markets.businessinsider.comHere's what to expect from Codexis's earningsMay 1, 2024 | msn.comCodexis Q1 2024 Earnings PreviewApril 26, 2024 | finance.yahoo.comWith 74% institutional ownership, Codexis, Inc. (NASDAQ:CDXS) is a favorite amongst the big gunsApril 19, 2024 | finance.yahoo.comCodexis, Inc. (CDXS)April 18, 2024 | globenewswire.comCodexis to Report First Quarter 2024 Financial Results on May 2April 11, 2024 | globenewswire.comCodexis Appoints Carole Cobb, MBA, to Strategic Advisory BoardSee More Headlines Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Industrial organic chemicals Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees174Year FoundedN/APrice Target and Rating Average Stock Price Target$7.33 High Stock Price Target$11.00 Low Stock Price Target$4.00 Potential Upside/Downside+98.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,240,000.00 Net Margins-87.73% Pretax Margin-87.65% Return on Equity-41.76% Return on Assets-24.61% Debt Debt-to-Equity Ratio0.35 Current Ratio3.71 Quick Ratio3.63 Sales & Book Value Annual Sales$74.23 million Price / Sales3.52 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.98Miscellaneous Outstanding Shares70,558,000Free Float69,076,000Market Cap$261.06 million OptionableOptionable Beta2.12 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Stephen George Dilly MBBS (Age 64)Ph.D., President, CEO & Director Comp: $1.88MMr. Sriram Ryali M.B.A. (Age 43)Chief Financial Officer Comp: $770.45kMr. Kevin Norrett M.B.A. (Age 51)M.S., Chief Operating Officer Comp: $739.56kCarrie McKimDirector of Investor RelationsMs. Margaret Nell Fitzgerald J.D. (Age 53)Chief Legal & Compliance Officer, General Counsel and Secretary Comp: $300.03kMs. Karen Frechou-ArmijoSenior VP & Head of Human ResourcesDr. Stefan Lutz Ph.D.Senior Vice President of ResearchMr. Robert Sato M.B.A.Ph.D., Senior Vice President of Pharmaceutical Development, Quality & RegulatoryMore ExecutivesKey CompetitorsFutureFuelNYSE:FFAmyrisNASDAQ:AMRSEmergent BioSolutionsNYSE:EBSLexicon PharmaceuticalsNASDAQ:LXRXVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 32,138 shares on 7/26/2024Ownership: 0.403%Baillie Gifford & Co.Sold 736,507 shares on 7/25/2024Ownership: 3.839%Assenagon Asset Management S.A.Sold 562,504 shares on 7/18/2024Ownership: 1.267%SG Americas Securities LLCBought 15,425 shares on 7/12/2024Ownership: 0.052%Opaleye Management Inc.Bought 74,475 shares on 5/29/2024Ownership: 4.422%View All Insider TransactionsView All Institutional Transactions CDXS Stock Analysis - Frequently Asked Questions How have CDXS shares performed this year? Codexis' stock was trading at $3.05 at the beginning of the year. Since then, CDXS stock has increased by 21.3% and is now trading at $3.70. View the best growth stocks for 2024 here. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $17.07 million for the quarter, compared to analyst estimates of $14.06 million. Codexis had a negative trailing twelve-month return on equity of 41.76% and a negative net margin of 87.73%. What is John J. Nicols' approval rating as Codexis' CEO? 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees. Who are Codexis' major shareholders? Codexis' top institutional shareholders include Baillie Gifford & Co. (3.84%), Assenagon Asset Management S.A. (1.27%), Bank of New York Mellon Corp (0.40%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett, Margaret Nell Fitzgerald, Dennis P Wolf and Patrick Y Yang. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH) and Intellia Therapeutics (NTLA). This page (NASDAQ:CDXS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
